Research Advances

A multicenter study has developed a predictive model to help identify pancreatic cancer patients who are unlikely to benefit from surgery after neoadjuvant therapy. The research focuses on pancreatic ductal adenocarcinoma patients who receive chemotherapy before surgery. Although this approach can improve outcomes, about 24% of patients still experience very poor results after surgery, with […]

A new mathematical model explains how living systems maintain order and resist disorder. The model views genes as active agents rather than static instructions. They produce enzymes that guide chemical reactions efficiently and steer them toward useful outcomes, helping cells stay organized. It also highlights how proteins consistently fold into precise 3D shapes despite many

A new study is reshaping understanding of pancreatic ductal adenocarcinoma (PDAC), showing that PI3K signaling—key to tumor growth—can persist without direct activation by mutant KRAS. Researchers found that a common mutation, KRAS G12R, cannot activate PI3K, yet tumors still maintain strong pathway activity, suggesting an alternative mechanism is at work. The study points to the

A new study highlights the Netrin-1 (NTN1) and Neogenin-1 (NEO1) signaling pathway as a major driver of pancreatic ductal adenocarcinoma (PDAC). Researchers found both proteins are highly overexpressed in tumors, fueled by KRAS mutations and stress signals from nearby nerves. These pathways create a self-reinforcing loop that supports tumor growth and spread. The research shows

Researchers are shifting how they treat pancreatic ductal adenocarcinoma (PDAC), focusing on the KRAS mutation that drives more than 90% of cases. This mutation locks KRAS in an “on” state, causing continuous cancer cell growth and making the disease resistant to many standard treatments, including immunotherapy. New findings show KRAS also shapes the tumor’s immune

Researchers have identified a key gene, SRRM1, that helps pancreatic cancer cells resist gemcitabine, the standard first-line chemotherapy. Higher levels of SRRM1 are linked to more advanced disease, metastasis, and poorer survival outcomes. When SRRM1 is blocked in resistant cancer cells, they become sensitive again to gemcitabine, suggesting it plays a central role in treatment

A long-term follow-up study of an individualized mRNA neoantigen vaccine for pancreatic cancer shows sustained immune activity and strong links to improved survival after surgery. Patients whose immune systems responded to the vaccine had not yet reached median recurrence-free survival after more than three years, while non-responders relapsed in about 13.4 months. The results suggest

Researchers have identified a surprising role for the immune receptor TREM2 in pancreatic cancer, where it appears to protect against tumor growth rather than promote it. In pancreatic ductal adenocarcinoma, higher levels of TREM2 are linked to more stable immune activity, while low TREM2 is associated with aggressive, inflammatory tumors. Using advanced single-cell analysis, scientists

Pancreatic cancer remains one of the deadliest cancers, with only about a 13% five-year survival rate. The main challenges are late diagnosis and strong resistance to treatment. Researchers are improving early detection by combining traditional markers like CA 19-9 with new methods such as microRNAs, DNA methylation, and liquid biopsy tests that analyze tumor DNA

A meta-analysis of 1,047 patients found that both intramedullary (IM) nailing and endoprosthetic (EP) reconstruction are effective options for treating femoral metastases, with the best choice depending on patient survival outlook and treatment goals. The study showed that IM nailing is associated with fewer early complications, including lower infection rates and fewer reoperations within the